Engflag

Tramset

Quick links to important sections

Tramset

Tramset_FR

Method of action: Analgesic, Analgesic Combination, Analgetic, Opioid

Treatment option: Pain

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tramset

Quick Facts

Property Description
Active ingredients Tramadol Hydrochloride, Acetaminophen (Paracetamol)
Form Oral tablet
Pharmacological class Combination Analgesic, CNS Agent
Common use Relief of moderate to moderately severe pain
Origin Synthetic Compound

What Type of Medicine is Tramset?

Tramset is the trade name for a Fixed-Dose Combination (FDC) Analgesic that acts upon the Central Nervous System (CNS) to alleviate pain. This synthetic medicine is a single oral tablet containing two distinct active pharmaceutical ingredients, classifying it as a prescription-only option. The formulation combines the weak opioid Tramadol Hydrochloride with the non-opioid pain reliever Acetaminophen (Paracetamol), a common analgesic strategy. Tramadol is specifically categorized as a Schedule IV controlled substance in the U.S., underscoring its restricted legal status.

This composition fundamentally defines the medicine’s classification, distinguishing it from single-agent formulations. Clinically, the combination is designed to provide a faster onset and more effective pain relief compared to Tramadol monotherapy, due to the complementary mechanisms of action. This FDC principle allows the medicine to target pain through multiple distinct pathways.

Understanding the Tramadol/Acetaminophen Combination

The central purpose of combining these two active ingredients into an FDC is to achieve a synergistic effect in pain management, where the combined analgesic action is greater than the sum of the individual agents. The Tramadol Hydrochloride component modulates pain signals via the μ-opioid receptor and neurotransmitter reuptake, while the Acetaminophen component interferes with central pain mediators. The use of this FDC is a recognized approach for providing broad-spectrum pain relief.

This integrated strategy aims to provide robust relief for moderate to moderately severe pain. The use of a fixed-ratio, co-formulated oral tablet is a practical differentiating feature, designed to simplify the pain management regimen and ensure the patient consistently receives the optimized blend of ingredients intended to produce a more effective analgesic response.

What side effects are possible with Tramset?

Possible Side Effects and Safety Information

Tramset (a combination of tramadol and acetaminophen) is subject to significant regulatory safety warnings due to its risks as an opioid-containing product.

Serious Warnings and Risks

Official regulatory labeling includes a Boxed Warning highlighting risks of Addiction, Abuse, and Misuse, which can lead to overdose and death. Life-threatening Respiratory Depression (slowed or stopped breathing) is a serious risk that may occur at any time, especially when therapy is initiated or the dose is increased. Accidental ingestion, particularly by children, can be fatal. Prolonged use during pregnancy can result in Neonatal Opioid Withdrawal Syndrome.

Additional serious risks include Serotonin Syndrome, which may be life-threatening and occurs most often with concomitant use of other serotonergic drugs, and the risk of Seizures (convulsions), which can occur even at recommended doses. Severe hepatotoxicity (liver damage) is associated with the acetaminophen component, especially if the maximum daily dose is exceeded or if combined with other acetaminophen-containing products.

Common Adverse Reactions

The most frequently reported side effects from clinical trials (classified as Very Common or Common) involve the central nervous system and the gastrointestinal system. These include nausea, dizziness, somnolence (drowsiness), vomiting, constipation, dry mouth, and headache.

Safety Restrictions and Contraindications

Tramset is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, or known or suspected gastrointestinal obstruction (such as paralytic ileus). It is also strictly contraindicated for use in children younger than 12 years of age, and in patients younger than 18 years following tonsillectomy and/or adenoidectomy.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Tramset

Overdose Scope

Property Description (As stated in official labeling)
Documented overdose presentations Presentation includes signs of opioid toxicity (e.g., miosis, somnolence, respiratory depression) combined with signs of Acetaminophen toxicity (e.g., pallor, nausea, vomiting, abdominal pain). Convulsions (seizures) and Serotonin Syndrome manifestations are also documented.
Physiological systems affected (as stated in label) Central Nervous System (CNS), Respiratory System, and Hepatic System (Liver).
Dose-related or exposure-related factors (if applicable) Overdose may occur when the recommended dose is exceeded. Accidental ingestion, particularly by children, is cited as a life-threatening exposure.
Population-specific overdose notes (if applicable) Risk is heightened in patients with severe hepatic impairment.
Emergency-response statements (as written in official documents) Treatment is symptomatic and supportive. Specific antidotes include Naloxone (for the opioid component) and N-acetylcysteine (NAC) (for the Acetaminophen component). Hospital monitoring is required.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for any suspected overdose or accidental ingestion, even if symptoms are not apparent.

Overdose Classifications (High-Level)

Property Description (As defined in official documents)
Severity classification (as defined in official documents) Classified as potentially leading to life-threatening respiratory depression, cardiovascular collapse, coma, and fatal hepatic necrosis (Acute Liver Failure).
Regulatory basis (EMA / FDA / etc.) The basis involves documented toxicity profiles from both Tramadol and Acetaminophen components.
Overdose-context constraints (as defined in official documents) The potential for delayed hepatic toxicity from the Acetaminophen component necessitates observation, even if the patient initially appears well.

Resulting Overdose Structure

Official overdose statements:

  • The most serious documented risks are life-threatening respiratory depression and hepatic necrosis, which can progress to acute liver failure.
  • Manifestations include miosis, somnolence, convulsions, metabolic acidosis, and early signs of gastrointestinal distress (nausea, vomiting, pallor).
  • Immediate medical attention is required for any suspected overdose or accidental exposure.
  • Management includes the administration of the specific antidotes Naloxone for opioid effects and N-acetylcysteine for Acetaminophen toxicity.
  • Hospital monitoring and specific laboratory tests are necessary due to the severe and potentially delayed nature of toxicity.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by detailing the dual-agent toxicity that concurrently threatens the CNS, respiratory, and hepatic systems. This definition mandates that treatment must address both the immediate opioid-related risks, such as respiratory compromise, and the delayed, potentially fatal liver damage from the acetaminophen component. The labeling explicitly requires that individuals seek immediate medical attention in all suspected overdose scenarios.

Therapeutic Uses of Tramset

What Tramset Treats: Main Uses and Benefits

This fixed-dose combination analgesic is applied to provide supportive relief for symptoms related to physical discomfort in situations where these manifestations may not be adequately addressed by initial non-opioid symptomatic support. The medication is commonly used in clinical settings where acute or disruptive symptom patterns require additional symptomatic support.

This medication is relevant when symptoms create noticeable interference with daily functioning, typically characterized by pain that falls into the moderate to moderately severe range. It is applied across domains involving heightened symptoms, such as painful manifestations associated with musculoskeletal conditions and discomfort following post-surgical recovery or non-surgical injury. The primary therapeutic benefit helps ease the overall symptom burden and supports general well-being during symptomatic phases. This approach is relevant when symptoms become temporarily overwhelming and require short-term symptomatic assistance.

Quick Fact Detail
Relief for Symptom Intensity Moderate to moderately severe range
Primary Therapeutic Benefit Easing overall symptom burden
Common Clinical Context Acute symptomatic episodes; conditions involving episodic manifestations

Regulatory References

  1. NIH DailyMed Drug Label Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Tramset?

Eligibility for using the combination medicine Tramset (Tramadol Hydrochloride and Acetaminophen) is defined by official regulatory documentation, primarily based on age, existing clinical conditions, and organ function. Use is generally restricted to adult patients (18 years and older).

Populations Prohibited from Use (Contraindicated)

The medicine is contraindicated in several specific populations, meaning its use is absolutely prohibited:

  • Children younger than 12 years of age.
  • Adolescents younger than 18 years following tonsillectomy and/or adenoidectomy.
  • Patients with severe hepatic (liver) impairment or uncontrolled epilepsy.
  • Individuals with significant respiratory depression or acute intoxication from alcohol, opioids, or certain other central nervous system depressants.
  • Patients who are taking or have recently taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.

Conditional and Restricted Use

Use is not recommended or requires special regulatory consideration in other groups:

  • Patients with moderate or severe renal (kidney) impairment.
  • Breastfeeding women.
  • Patients over 75 years old may require an adjustment to the minimum interval between doses.

The regulatory profile mandates careful risk assessment for use during pregnancy, as prolonged use can result in Neonatal Opioid Withdrawal Syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for this fixed-dose combination analgesic details several drug interaction types, ranging from prohibited combinations to substances that modify systemic exposure.

Category Description / Entity
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, Serotonergic Drugs, Drugs that Lower the Seizure Threshold, CYP2D6/CYP3A4 Inhibitors, CYP3A4 Inducers, Anticoagulants.
Specific interacting medicines (if explicitly listed) Carbamazepine, Warfarin, Fluoxetine, Quinidine.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (CYP-mediated inhibition or induction); Pharmacodynamic interaction (additive CNS depression; additive serotonergic activity).
Timing-based interaction rules (if applicable) MAOIs require a mandatory 14-day washout period before initiation.
Population-specific interaction notes (if applicable) Increased exposure risk is noted for patients with severe renal impairment and severe hepatic impairment.
Interaction-related restrictions Contraindication of concurrent use with MAOIs; Prohibition against co-administration with other tramadol- or acetaminophen-containing products.

Official Interaction Statements:

  • Co-administration with MAOIs is contraindicated, with a required 14-day period following MAOI cessation.
  • Concomitant use with CNS Depressants (including alcohol) is officially restricted due to the risk of profound sedation and respiratory depression.
  • Co-administration with Serotonergic Drugs is associated with an increased risk of Serotonin Syndrome.
  • CYP2D6 and CYP3A4 Inhibitors may cause a pharmacokinetic interaction leading to increased exposure of the parent drug, Tramadol, or reduced exposure of its active metabolite.
  • Use with Coumarin derivatives (e.g., Warfarin) requires caution due to regulatory reports of altered laboratory prothrombin time (INR).

This structure establishes necessary prohibitions and risk classifications based on the potential for augmented CNS depression, serotonin overload, and metabolic changes, as documented in government prescribing information.

Mechanism of Action

Tramset functions as a selective, non-competitive inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS). This enzyme is a critical component of the mevalonate pathway, responsible for catalyzing the synthesis of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). Tramset binds to an allosteric site on FPPS, inducing a conformational change that prevents the formation of these isoprenoid intermediates. The resulting depletion of FPP and GGPP disrupts a necessary post-translational modification known as protein prenylation. This process is essential for anchoring various small GTPases, such as Ras, Rho, and Rac, to the cellular membrane. Without proper lipid anchoring, these signaling proteins remain sequestered in the cytosol, preventing their activation and their subsequent engagement in intracellular signaling cascades. This molecular cascade leads to the modulation of fundamental cellular processes, including cell cycle progression and cell motility, across affected tissues.

Dosage and Administration Information

How to Use Tramset: Administration Guidelines

Tramset, the fixed-dose combination tablet containing 37.5 mg of tramadol and 325 mg of acetaminophen, is strictly approved for oral administration only. Standard guidance for its use centers on precise dosing, time intervals, and duration.

Administration Scope

Category Instruction
Route of administration Oral (by mouth) only.
Dosing schedule The recommended starting dose is 2 tablets. The maximum dose is strictly limited to 8 tablets per 24-hour period.
Timing in relation to meals May be taken with or without food.
Preparation requirements Tablets must be swallowed whole and must not be crushed, broken, or dissolved.
Age-group administration rules The medicine is not established for use in pediatric patients. Use is not recommended in cases of severe hepatic impairment.
Special procedural conditions For severe renal impairment (CrCl < 30 mL/min), the maximum dose is restricted to 2 tablets every 12 hours.

Instruction Classifications

Classification Detail
Frequency pattern As-needed (PRN) dosing, with a minimum interval of 4 to 6 hours between doses.
Use-context constraints Must not be co-administered with any other product containing tramadol or acetaminophen. Treatment is limited to a short-term course of five days or less.

Connection to the Overall Use Protocol

Established protocols define the specific boundaries for Tramset usage, mandating a fixed oral dose range and a required time interval to ensure the total daily intake of both active ingredients remains within approved limits. Furthermore, the protocol specifies that treatment is primarily for acute, short-term needs, and that gradual tapering is necessary upon discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tramset

This section provides an overview of the official research studies and clinical trials that have been conducted to understand this fixed-dose combination medicine. This information is purely descriptive and does not offer clinical advice or recommendations.

Evidence for Use in Acute Pain Conditions

Clinical evaluation of this medicine for short-term symptom relief relies primarily on short-term, randomized controlled trials (RCTs). These studies were relevant in trials assessing episodic symptom patterns, such as pain experienced after surgical procedures like dental extractions or general surgery recovery. Researchers typically measured pain intensity difference and total pain relief over a limited, short-term duration, often over 24 to 48 hours, to see how symptoms changed over time.

Studies conducted during periods of increased symptom activity reported observations showing patterns related to changes in pain relief scores compared to placebo in the immediate post-treatment period. Findings help contextualize how patients reported their experience, suggesting that changes in pain relief scores were observed in some studies involving short-term use for acute pain settings.

Evidence for Use in Chronic Pain Conditions

The research base for conditions associated with chronic symptoms includes intermediate-term randomized controlled trials and observational settings that evaluated daily-life functioning. Studies explored the use of this fixed-dose combination for conditions characterized by functional limitations and periods of heightened symptoms.

Evidence for Osteoarthritis

This combination was evaluated in studies exploring outcomes related to physical discomfort and daily functioning in adults with osteoarthritis of the knee or hip. Trials typically lasted several weeks to a few months. Researchers monitored changes in pain scores using standardized numerical scales and explored functional status using measures like the WOMAC index.

Evidence for Other Chronic Pain Syndromes

The research base for more complex chronic pain syndromes, such as fibromyalgia and certain types of chronic low back pain, consists of both RCTs and observational studies. Trials for these indications reported observations of differences in pain intensity scores between the fixed-dose combination and placebo over several weeks of study duration. Findings were often noted to be heterogeneous across these specific pain types.

Research Gaps and Areas of Uncertainty

Comparative evidence is lacking in some areas, making it difficult to fully contextualize the findings alongside other non-opioid or single-agent therapies. The primary gap is the limited information for long-term outcomes, meaning the symptom patterns observed beyond a few months are not fully established by the existing evidence. Furthermore, sample sizes were modest for many subgroup analyses, and data for certain groups remain insufficient to draw broad conclusions.

Key Studies & References

  1. Tramadol Hydrochloride and Acetaminophen Tablet: Official FDA Label and Medication Guide (DailyMed)

How should Tramset be stored and disposed of?

Tramset (Tramadol/Acetaminophen) must be stored and disposed of according to official regulatory requirements, primarily due to its classification as a controlled substance.

Item Requirement (Based on Official Regulatory Documentation)
Labeled storage temperature requirements: Store at Controlled Room Temperature, between 20^circC and 25^circC (68^circF to 77^circF).
Light/moisture protection requirements: Keep in the original container, tightly closed, and protected from excessive moisture.
Child-protection storage requirements: MANDATORY: Keep the medicine out of the sight and reach of children and store it securely to prevent theft or accidental overdose.
Disposal instructions: The preferred method is to use a drug take-back program. If this is unavailable, the U.S. FDA advises flushing the tablets down the toilet immediately to prevent high-risk accidental ingestion.

Official regulatory documents define the storage by strictly specifying the required temperature and moisture protection for product stability. The disposal rules are determined by the Tramadol component, mandating secure storage and controlled disposal to prevent both diversion and accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndonesia

Equivalent of Tramset found in:

A-Z Index: